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CD4 and CD8 Coexpressed T-Lymphocytosis in Adult
Onset Still’s Disease
To the Editor: Adult onset Still’s disease (AOSD) is a febrile disorder with
typical spiking fever, evanescent rash and involvement of various organs.
Although increase of TCRgd+ T cells in peripheral blood lymphocyte
(PBL) were reported, the details of T-cell abnormalities in the AOSD
remain obscure [1]. According to normal T-cell ontogeny, T cells in PBL
typically express high density of T-cell receptor/CD3 complex and either
CD4 or CD8 surface antigens. T lymphocytes bearing only CD4 or CD8
are released in the circulation after a maturation process in the cortex where
most T lymphocytes simultaneously coexpress CD4 and CD8 antigens.
However, a very low percentage (1–2%) of T cells that coexpress CD4 and
CD8 also are found in the PBL. We report herein a patient of adult onset
Still’s disease with CD4/8 coexpressed lymphocytosis.
A 20-year-old woman had diagnosis of AOSD according to the 1992
criteria, proposed by Yamaguchi [2]. Six months later, she was admitted
with fever, vomiting, and arthralgia. Examinations on admission revealed
a blood pressure of 120/60 mmHg, body temperature of 39.8°C, tachycar-
dia, macular eruption on the neck, and trunk. Although the hemoglobin,
white blood cells (WBC), and platelet were normal at the time of admis-
sion, leukocytosis, anemia and thrombocytopenia developed after 2 weeks.
On day 16 of the admission, the patient’s WBC rose to 74.6 × 109/l
(neutrophils 28%, lymphocytes 38%, reactive lymphocytes 28%, mono-
cytes 3%, eosinophils 3%) and hemoglobin and platelets dropped to 7.9
g/dl and 61.0 × 109/l, respectively. PBL showed 97.6% T cells (CD3+),
4.7% NK cells (CD16/56+), and less than 1% B cells (CD19+). T-cell
subsets were analysed as follows; CD4+/CD8− 8.9%, CD4+/CD8+ 19.9%,
CD4−/CD8+ 68.8%. Markedly increased liver enzyme (AST 524 IU/l,
ALT 59 IU/l), and hyperferritinemia (155,010 mg/l) were observed. Posi-
tive fibrin/fibrinogen degradation product and D-dimer, decreased levels of
fibrinogen and anti-thrombin III, presence of schistocytes, prolonged pro-
thrombin, and activated partial thromboplastin time revealed disseminated
intravascular coagulation (DIC) state. Blood, urine, and stool cultures were
negative. Serologic evaluations for viral markers, including hepatitis B and
C, Epstein-Barr, cytomeglovirus, herpes simplex, and varicella were all
negative. The course of the disease was refractory to steroid pulse therapy
and the patient died from DIC and hepatic failure.
Although the increase of CD4+CD8+ cells in PBL has been reported
previously in a few benign disorders such as idiopathic thrombocytopenic
purpura, Behcet’s syndrome, myasthenia gravis, and one normal adult male
[3,4], this is the first report of AOSD with CD4+CD8+ lymphocytosis. The
clinical significance of large numbers of circulating CD4+CD8+ cells is
not clear at this time. This finding may represent the manifestation of
enhanced or abnormal immune reactivity in AOSD.
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Vancomycin-Induced Thrombocytopenia
To the Editor: Vancomycin is widely used to treat Gram-positive bacterial
infections. Vancomycin-associated thrombocytopenia has been reported
and ascribed to an immunological mechanism [1–3]. In these rare reports,
patients had chemotherapy-induced pancytopenia that could not be distin-
guished from the effects of vancomycin. We report a patient who devel-
oped severe thrombocytopenia during vancomycin therapy that resolved
promptly after cessation of therapy.
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A 72-year-old white male with metastatic pancreatic cancer on gem-
citabine was started on vancomycin for staphylococcal sepsis after recov-
ery of his peripheral blood counts (side effect of gemcitabine). After sur-
gery for associated cervical spinal cord compression, which revealed staph-
ylococcal epidural abscess, a 6-week course of vancomycin therapy was
planned. After 12 days of therapy with vancomycin, he developed throm-
bocytopenia, which became severe on day 18 (platelet count 13 × 103/ml)
and did not respond to platelet transfusions (Fig. 1). A bone marrow biopsy
showed adequate megakaryocytes. Platelet-associated immunoglobulin as-
say by flow cytometry showed elevated IgG level (4.66) and IgG index
(5.19), as well as elevated IgM levels (7.16) and IgM index (7.97). (Normal
IgG level 1.18, IgG index 2.67, IgM level 1.43, IgM index 4.24; negative
patient IgG level 0.63, IgG index 1.54, IgM level 1.03, IgM index 2.49).
Vancomycin therapy was discontinued on day 28 and trimethoprim/
sulfmethoxazole was administered, with prompt recovery of his platelet
count from 13 × 103/ml to 136 × 103/ml in 10 days (Fig. 1).
Thrombocytopenia during vancomycin therapy has previously been de-
scribed in patients with decreased platelet production due to intrinsic bone
marrow disease or bone marrow toxicity. Although some of these patients
had vancomycin-dependent antiplatelet antibodies and resolution of throm-
bocytopenia after cessation of vancomycin therapy, the role of immune
mediated platelet destruction was not established [3]. Our patient had ad-
equate bone marrow megakaryocytes, failed to respond to platelet trans-
fusions, had increased platelet-associated immunoglobulins, and had rapid
recovery of the platelet count after cessation of therapy, suggesting im-
mune thrombocytopenia. The temporal relationship between the start of
vancomycin therapy, detection of thrombocytopenia and rapid recovery
after stopping vancomycin suggests that vancomycin-induced immune
thrombocytopenia can be an independent cause of thrombocytopenia in
patients with adequate platelet production.
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Transient Cytomegalovirus-Induced Hemolysis in an
Immunocompetent Woman
To the Editor: Previously, cytomegalovirus (CMV)-induced hemolysis
with negative direct antiglobulin test in immunocompetent adults which
responded to treatment with ganciclovir or high-dose gamma-globulin have
been reported [1,2]. We here report a new case of CMV-induced hemolysis
with negative direct antiglobulin test and that associated with increased
osmotic fragility.
A 18-year-old woman was admitted to our hospital with 6 days history
of fever and general malaise. Physical examination revealed anemia, ic-
terus, together with fever (38.1°C). A blood examination revealed hemo-
globin (Hb) 7.4 g/dl, white blood cells 13.2 × 109/l, and platelets counts
401 times 109/l. Reticulocyte percentage was 4.8%. The blood film re-
vealed no red cell fagmentations and spherocytes. Serum chemistry values
were as follows: bilirubin 2.4 mg/dl; alanine aminotransferase 129 IU/l;
aspartate aminotransferase 298 IU/l; lactate dehydrogenase 1,009 IU/l. Di-
rect antiglobulin test was repeatedly negative and serum haptoglobin level
was undetectable. Immunological tests including cryoglobulins, cold ag-
glutinins, rheumatic factor, and antinuclear antibodies were negative. The
bone marrow picture showed erythroid hyperplasia. Parvovirus DNA was
not detected in the serum by polymerase chain reaction. However, the
detection of IgM antibodies to CMV on three consecutive occasions and
demonstration of a four-fold rise in the IgG titre in the month following
presentation suggested an active CMV infection. After diagnosis was made
of hemolytic anemia with negative direct antiglobulin test, we performed
the following tests. Ham and sugar water tests were negative. Pattern of
haemoglobin fraction was normal. Red cell enzyme activities of glucose-
6-phosphate dehydrogenase and pyruvate kinase were normal. Red cells
osmotic fragility test (Parpart’s method) revealed increased osmotic fra-
gility (Fig. 1, m). Because she did not have symptoms due to anemia, the
clinical course was carefully followed with no treatment. After 4-weeks
from admission, the Hb level spontaneously increased to 11.4 g/dl and the
haptoglobin level recovered to normal range (97 mg/dl). Osmotic fragility
test was reexamined and osmotic fragility was normal (Fig. 1, d). She has
been regularly followed for more than 3 months after initial presentation
and is well without any symptoms or signs of hemolysis.
CMV-induced hemolysis with positive direct antiglobulin test was well
described [3,4]. CMV-induced hemolysis with negative direct antiglobulin
test in which responded to treatment with ganciclovir or high-dose gamma-
globulin have been also reported [1,2]. In contrast to previous reports,
spontaneous improvements of hemolysis and osmotic fragility were ob-
served in our case. The mechanism for CMV-induced hemolysis is unclear.
Because increased osmotic fragility spontaneously improved together with
improvement of hemolysis, we speculated that CMV infection induced an
increase in red cells osmotic fragility. In the future, red cells osmotic
Fig. 1. Relationship of platelet counts to the administration
of vancomycin. The initial chemotherapy induced thrombo-
cytopenia recovered promptly. Subsequent vancomycin
therapy was associated with thrombocytopenia that did not
respond to platelet transfusions ( fl ), but promptly recovered
after the discontinuation of the drug.
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fragility test should be performed when encountering the patients of CMV-
induced hemolysis with negative direct antiglobulin test.
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Decreased Expression of the Fas Ligand on Peripheral
Blood Mononuclear Cells and Undetectable Levels of
Soluble Fas Ligand in the Serum of Patients With Aplastic
Anemia and Myelodysplastic Syndrome
To the Editor: Increased expression of Fas antigen (Fas) is observed in the
hematopoietic progenitors of aplastic anemia [1] and myelodysplastic syn-
drome (MDS) [2]; thus, increased apoptosis has been considered a patho-
genetic mechanism of these disorders [1,2].
Fas ligand (FasL) is a cell type II transmembrane protein homologous to
members of tumor necrosis factor (TNF) family, is mainly expressed on
natural killer cells and T lymphocytes, and induces apoptosis by binding to
its receptor, Fas [3]. Fas L exists into two forms; an insoluble form that is
membrane-bound—mFasL—and a soluble form—sFasL—which is
cleaved from mFasL by metalloproteinase, consists of an extracellular
region of FasL [4], and was recently found to down-regulate mFasL by
shedding depending on the cells [5].
The pathological significance of the Fas L system (mFasL and sFasL) on
the pathogenesis of aplastic anemia and MDS is unknown.
We studied 8 patients with severe or moderate aplastic anemia, 12 pa-
tients with MDS including 9 patients with refractory anemia (RA) and 3
patients with RA with excess of blasts (RAEB).
The expression of mFasL on peripheral blood mononuclear cells was
measured by flow cytometry using anti-human Fas L monoclonal antibody
(Medical and Biological Laboratories, Nagoya, Japan). sFasL levels in the
serum were measured by using the enzyme-linked immunosorbent assay
kit produced by the same laboratory.
The expression of Fas L on peripheral blood mononuclear cells was
significantly reduced in patients with aplastic anemia (6.3 ± 2.8%, mean ±
SD, p 4 0.0025) and MDS (5.6 ± 2.4, p < 0.0001) compared to those in
normal controls (10.1 ± 1.8) (Fig. 1).
sFasL was not elevated and was undetectable in all patients with aplastic
anemia and MDS; <0.31 ng/ml.
The present results indicate that the signaling of apoptosis for the cyto-
Fig. 1. Osmotic fragility curves (Parpart’s method). The pa-
tient’s blood was defibrinated and incubated for 24 hr at
37°C. (m) At admission, (d) after 4-weeks. The shaded area
indicates normal range.
Fig. 1. The expression of the Fas L on peripheral blood
mononuclear cells of patients with aplastic anemia (A), my-
elodysplastic syndrome (M), and normal controls (N).
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toxicity by these Fas L systems is not always accentuated in aplastic
anemia and MDS. The results indicate the following possible mechanisms.
The Fas system-dependent T-cell mediated cytotoxicity may only act when
lymphocytes bearing the Fas L are activated by certain stimuli including
viral infection or cytokines such as TNF-a or interferon-g, and this effect
may occur locally in the bone marrow [6]. It was demonstrated that a small
amount of interferon-g constitutively expressed in the stromal microenvi-
ronment of human marrow culture-mediated potent hemetopoietic inhibi-
tion [7]. The same phenomenon as in AIDS may operate in that a small
fraction of Fas L bearing cells or low concentrations of sFasL work [8]. Or,
cytokine such as TNF-a may activate TNF receptor of the target hemato-
poietic cells and induce apoptosis without via Fas L system [6]. More
detailed study is necessary.
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